Effects of (R)-ketamine on reduced bone mineral density in ovariectomized mice: A role of gut microbiota
We reported that the novel antidepressant (R)-ketamine could ameliorate the reduced BMD in the ovariectomized (OVX) mice which is an animal model of postmenopausal osteoporosis. Given the role of gut microbiota in depression and bone homeostasis, we examined whether gut microbiota plays a role in the beneficial effects of (R)-ketamine in the reduced BMD of OVX mice. OVX or sham was operated for female mice. Subsequently, saline (10 ml/kg/day, twice weekly) or (R)-ketamine (10 mg/kg/day, twice weekly) was administered intraperitoneally into OVX or sham mice for the six weeks. The reduction of cortical BMD and total BMD in t...
Source: Neuropharmacology - May 20, 2022 Category: Drugs & Pharmacology Authors: Xiayun Wan Akifumi Eguchi Yuko Fujita Li Ma Xingming Wang Yong Yang Youge Qu Lijia Chang Jiancheng Zhang Chisato Mori Kenji Hashimoto Source Type: research

Protective effects of phosphodiesterase 2 inhibitor against A β < sub > 1-42 < /sub > induced neuronal toxicity
Neuropharmacology. 2022 May 16:109128. doi: 10.1016/j.neuropharm.2022.109128. Online ahead of print.ABSTRACTOur previous study suggested that inhibition of Phosphodiesterase 2 ameliorates memory loss upon exposure to oxidative stress. While whether memory enhancing effects of PDE2 inhibition on Alzheimer's disease mouse model are involved in antioxidant defense and neuronal remodeling, are largely unexplored. The present study addressed whether and how PDE2 inhibitor Bay 60-7550 rescued Aβ oligomers (Aβo)-induced neuronal damage and memory impairment. The results suggested that exposure of primary cortical neurons to Aβ...
Source: Neuropharmacology - May 19, 2022 Category: Drugs & Pharmacology Authors: Yuqing Yan Shichao Gao Shivani Avasthi Yuhan Zhao Jianghong Ye Yuanxiang Tao Wei Wang Xiongwei Zhu Fu Du James M O'Donnell Ying Xu Source Type: research

NADPH oxidase-induced activation of transforming growth factor-beta-1 causes neuropathy by suppressing antioxidant signaling pathways in alcohol use disorder
In conclusion, this study significantly extends our understanding of the pathophysiology of AUD and provides a unique insight for developing various therapeutic interventions by activating antioxidant signaling pathways for the treatment of AUD-induced neurological complications.PMID:35584723 | DOI:10.1016/j.neuropharm.2022.109136 (Source: Neuropharmacology)
Source: Neuropharmacology - May 18, 2022 Category: Drugs & Pharmacology Authors: Saurav Bhowmick Saleena Alikunju P M Abdul-Muneer Source Type: research

NADPH oxidase-induced activation of transforming growth factor-beta-1 causes neuropathy by suppressing antioxidant signaling pathways in alcohol use disorder
In conclusion, this study significantly extends our understanding of the pathophysiology of AUD and provides a unique insight for developing various therapeutic interventions by activating antioxidant signaling pathways for the treatment of AUD-induced neurological complications.PMID:35584723 | DOI:10.1016/j.neuropharm.2022.109136 (Source: Neuropharmacology)
Source: Neuropharmacology - May 18, 2022 Category: Drugs & Pharmacology Authors: Saurav Bhowmick Saleena Alikunju P M Abdul-Muneer Source Type: research

Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations
This report calls attention to this concern by detailing the challenges and opportunities associated with evaluating psilocybin-facilitated psychotherapy in vulnerable populations. First, we show how working with vulnerable populations must be considered in the context of an often-problematic past and differential exposure to and experience with classic psychedelics. We then provide actionable recommendations for future research testing psilocybin-facilitated psychotherapy in vulnerable populations, including an emphasis on recruitment strategies, the appropriate communication and assessment of subjective effects, building...
Source: Neuropharmacology - May 16, 2022 Category: Drugs & Pharmacology Authors: Cynthia E Ortiz Haley Maria Dourron Noah W Sweat Albert Garcia-Romeu Sarah MacCarthy Brian T Anderson Peter S Hendricks Source Type: research

Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations
This report calls attention to this concern by detailing the challenges and opportunities associated with evaluating psilocybin-facilitated psychotherapy in vulnerable populations. First, we show how working with vulnerable populations must be considered in the context of an often-problematic past and differential exposure to and experience with classic psychedelics. We then provide actionable recommendations for future research testing psilocybin-facilitated psychotherapy in vulnerable populations, including an emphasis on recruitment strategies, the appropriate communication and assessment of subjective effects, building...
Source: Neuropharmacology - May 16, 2022 Category: Drugs & Pharmacology Authors: Cynthia E Ortiz Haley Maria Dourron Noah W Sweat Albert Garcia-Romeu Sarah MacCarthy Brian T Anderson Peter S Hendricks Source Type: research

Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations
This report calls attention to this concern by detailing the challenges and opportunities associated with evaluating psilocybin-facilitated psychotherapy in vulnerable populations. First, we show how working with vulnerable populations must be considered in the context of an often-problematic past and differential exposure to and experience with classic psychedelics. We then provide actionable recommendations for future research testing psilocybin-facilitated psychotherapy in vulnerable populations, including an emphasis on recruitment strategies, the appropriate communication and assessment of subjective effects, building...
Source: Neuropharmacology - May 16, 2022 Category: Drugs & Pharmacology Authors: Cynthia E Ortiz Haley Maria Dourron Noah W Sweat Albert Garcia-Romeu Sarah MacCarthy Brian T Anderson Peter S Hendricks Source Type: research

Effects of GPR139 agonism on effort expenditure for food reward in rodent models: Evidence for pro-motivational actions
Neuropharmacology. 2022 May 10:109078. doi: 10.1016/j.neuropharm.2022.109078. Online ahead of print.ABSTRACTApathy, deficiency of motivation including willingness to exert effort for reward, is a common symptom in many psychiatric and neurological disorders, including depression and schizophrenia. Despite improved understanding of the neurocircuitry and neurochemistry underlying normal and deficient motivation, there is still no approved pharmacological treatment for such a deficiency. GPR139 is an orphan G protein-coupled receptor expressed in brain regions which contribute to the neural circuitry that controls motivation...
Source: Neuropharmacology - May 13, 2022 Category: Drugs & Pharmacology Authors: Alexandra M ünster Susanne Sommer Diana K úkeľová Hannes Sigrist Eliza Koros Serena Deiana Klaus Klinder Tamara Baader-Pagler Svenja Mayer-Wrangowski Boris Ferger Tom Bretschneider Christopher R Pryce Wolfgang Hauber Moritz von Heimendahl Source Type: research

Discrimination of motor and sensorimotor effects of phencyclidine and MK-801: Involvement of GluN2C-containing NMDA receptors in psychosis-like models
Neuropharmacology. 2022 May 10:109079. doi: 10.1016/j.neuropharm.2022.109079. Online ahead of print.ABSTRACTNon-competitive NMDA receptor (NMDA-R) antagonists like ketamine, phencyclidine (PCP) and MK-801 are routinely used as pharmacological models of schizophrenia. However, the NMDA-R subtypes, neuronal types (e.g., GABA vs. glutamatergic neurons) and brain regions involved in psychotomimetic actions are not fully understood. PCP activates thalamo-cortical circuits after NMDA-R blockade in reticular thalamic GABAergic neurons. GluN2C subunits are densely expressed in thalamus and cerebellum. Therefore, we examined their ...
Source: Neuropharmacology - May 13, 2022 Category: Drugs & Pharmacology Authors: Mireia Tarr és-Gatius Ximena L ópez-Hill Llu ís Miquel-Rio Laura Castarlenas Sara Fabius Noem í Santana M Teresa Vilar ó Francesc Artigas Mar ía Cecilia Scorza Anna Casta ñé Source Type: research

Effects of GPR139 agonism on effort expenditure for food reward in rodent models: Evidence for pro-motivational actions
Neuropharmacology. 2022 May 10:109078. doi: 10.1016/j.neuropharm.2022.109078. Online ahead of print.ABSTRACTApathy, deficiency of motivation including willingness to exert effort for reward, is a common symptom in many psychiatric and neurological disorders, including depression and schizophrenia. Despite improved understanding of the neurocircuitry and neurochemistry underlying normal and deficient motivation, there is still no approved pharmacological treatment for such a deficiency. GPR139 is an orphan G protein-coupled receptor expressed in brain regions which contribute to the neural circuitry that controls motivation...
Source: Neuropharmacology - May 13, 2022 Category: Drugs & Pharmacology Authors: Alexandra M ünster Susanne Sommer Diana K úkeľová Hannes Sigrist Eliza Koros Serena Deiana Klaus Klinder Tamara Baader-Pagler Svenja Mayer-Wrangowski Boris Ferger Tom Bretschneider Christopher R Pryce Wolfgang Hauber Moritz von Heimendahl Source Type: research

Discrimination of motor and sensorimotor effects of phencyclidine and MK-801: Involvement of GluN2C-containing NMDA receptors in psychosis-like models
Neuropharmacology. 2022 May 10:109079. doi: 10.1016/j.neuropharm.2022.109079. Online ahead of print.ABSTRACTNon-competitive NMDA receptor (NMDA-R) antagonists like ketamine, phencyclidine (PCP) and MK-801 are routinely used as pharmacological models of schizophrenia. However, the NMDA-R subtypes, neuronal types (e.g., GABA vs. glutamatergic neurons) and brain regions involved in psychotomimetic actions are not fully understood. PCP activates thalamo-cortical circuits after NMDA-R blockade in reticular thalamic GABAergic neurons. GluN2C subunits are densely expressed in thalamus and cerebellum. Therefore, we examined their ...
Source: Neuropharmacology - May 13, 2022 Category: Drugs & Pharmacology Authors: Mireia Tarr és-Gatius Ximena L ópez-Hill Llu ís Miquel-Rio Laura Castarlenas Sara Fabius Noem í Santana M Teresa Vilar ó Francesc Artigas Mar ía Cecilia Scorza Anna Casta ñé Source Type: research

The NOP antagonist BTRX-246040 increases stress resilience in mice without affecting adult neurogenesis in the hippocampus
This study, performed with a clinically viable ligand, further corroborates growing evidence indicating that the blockade of the NOP signaling may provide an innovative strategy for the treatment of stress related psychopathologies.PMID:35513173 | DOI:10.1016/j.neuropharm.2022.109077 (Source: Neuropharmacology)
Source: Neuropharmacology - May 5, 2022 Category: Drugs & Pharmacology Authors: Flora D'Oliveira da Silva Joaquim Azevedo Neto Chiara Sturaro Annunziata Guarino Cathaline Robert Elaine C Gavioli Girolamo Calo Lionel Mouledous Chiara Ruzza Source Type: research

The NOP antagonist BTRX-246040 increases stress resilience in mice without affecting adult neurogenesis in the hippocampus
This study, performed with a clinically viable ligand, further corroborates growing evidence indicating that the blockade of the NOP signaling may provide an innovative strategy for the treatment of stress related psychopathologies.PMID:35513173 | DOI:10.1016/j.neuropharm.2022.109077 (Source: Neuropharmacology)
Source: Neuropharmacology - May 5, 2022 Category: Drugs & Pharmacology Authors: Flora D'Oliveira da Silva Joaquim Azevedo Neto Chiara Sturaro Annunziata Guarino Cathaline Robert Elaine C Gavioli Girolamo Calo Lionel Mouledous Chiara Ruzza Source Type: research

The NOP antagonist BTRX-246040 increases stress resilience in mice without affecting adult neurogenesis in the hippocampus
This study, performed with a clinically viable ligand, further corroborates growing evidence indicating that the blockade of the NOP signaling may provide an innovative strategy for the treatment of stress related psychopathologies.PMID:35513173 | DOI:10.1016/j.neuropharm.2022.109077 (Source: Neuropharmacology)
Source: Neuropharmacology - May 5, 2022 Category: Drugs & Pharmacology Authors: Flora D'Oliveira da Silva Joaquim Azevedo Neto Chiara Sturaro Annunziata Guarino Cathaline Robert Elaine C Gavioli Girolamo Calo Lionel Mouledous Chiara Ruzza Source Type: research

The NOP antagonist BTRX-246040 increases stress resilience in mice without affecting adult neurogenesis in the hippocampus
This study, performed with a clinically viable ligand, further corroborates growing evidence indicating that the blockade of the NOP signaling may provide an innovative strategy for the treatment of stress related psychopathologies.PMID:35513173 | DOI:10.1016/j.neuropharm.2022.109077 (Source: Neuropharmacology)
Source: Neuropharmacology - May 5, 2022 Category: Drugs & Pharmacology Authors: Flora D'Oliveira da Silva Joaquim Azevedo Neto Chiara Sturaro Annunziata Guarino Cathaline Robert Elaine C Gavioli Girolamo Calo Lionel Mouledous Chiara Ruzza Source Type: research